Relapse · guttate psoriasis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Time‐to‐resolution: achieving PASI 90 to 100 or PGA 0 to 1 · guttate psoriasis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Proportion of participants with adverse events and severe adverse events · guttate psoriasis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Proportion of participants achieving clear or almost clear skin (PASI 90 to 100 or PGA 0 to 1) · guttate psoriasis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Proportion of participants achieving PASI 75 or PGA 1 to 2 · guttate psoriasis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Microbiological cure · Pregnant women with a confirmed Chlamydia trachomatis infection
Erythromycin probably leads to higher microbiological cure compared with placebo (moderate certainty).
1 finding from 1 review
Clinical failure clinical observation · patients with BCG adverse reactions1
It is very uncertain whether oral erythromycin changes clinical failure clinical observation compared with placebo or no intervention (very low certainty).
1 finding from 1 review
Clinical cure: syndromic approach · sexually active adults
Macrolide (erythromycin) showed no clear difference in clinical cure: syndromic approach compared with any other macrolide (low certainty).
1 finding from 1 review
Clinical cure: aetiological approach · sexually active adults
Macrolide (erythromycin) showed no clear difference in clinical cure: aetiological approach compared with any other macrolide (low certainty).
1 finding from 1 review
Minor adverse events · sexually active adults
It is very uncertain whether macrolide (erythromycin) changes minor adverse events compared with any other macrolide (very low certainty).
1 finding from 1 review
All‐cause mortality · people with acute UGIH
It is very uncertain whether erythromycin plus nasogastric tube lavage changes all‐cause mortality compared with no intervention/placebo plus nasogastric tube lavage (very low certainty).
1 finding from 1 review
Visualisation of gastric mucosa · people with acute UGIH
1 finding from 1 review
NSAEs · people with acute UGIH
It is very uncertain whether erythromycin plus nasogastric tube lavage changes NSAEs compared with no intervention/placebo plus nasogastric tube lavage (very low certainty).
1 finding from 1 review
Rebleeding · people with acute UGIH
It is very uncertain whether erythromycin plus nasogastric tube lavage changes rebleeding compared with no intervention/placebo plus nasogastric tube lavage (very low certainty).
1 finding from 1 review
Blood transfusion · people with acute UGIH
1 finding from 1 review
UGIH‐related mortality · people with acute UGIH
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
SAEs · people with acute UGIH
1 finding from 1 review
All‐cause mortality · people with acute UGIH
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Visualisation of gastric mucosa · people with acute UGIH
It is very uncertain whether erythromycin plus nasogastric tube lavage changes visualisation of gastric mucosa compared with metoclopramide plus nasogastric tube lavage (very low certainty).
1 finding from 1 review
NSAEs · people with acute UGIH
1 finding from 1 review